Healthcare & Life Sciences Blog -

Germany’s implementation of the European Accessibility Act (EAA) – Are medical devices affected?

by Dr. Frank Pflueger

EU Pharmaceutical Package

Council Clears Path to Trilogue on Pharma Package with Reduced Market Protection and stepped up Access Obligations

by Dr. Martin Altschwager LL.M., Els Janssens, Juliusz Krzyżanowski, Olha Sviatenka and Magda Tovar

Pharmaceuticals & Biotech

External Control Arms Based on Real World Data: MHRA Consultation Opens

by Jaspreet Takhar, Julia Gillert and Elina Angeloudi

Medical Devices

The EU AI Act and Medical Devices: Innovation or Insanity Ahead?

by Jaspreet Takhar, Julia Gillert and Elina Angeloudi

Pharmaceuticals & Biotech

New White House Executive Order to Establish “Most-Favored-Nation” Drug Pricing

by Michelle Carr, Kerry B. Contini, Maria Eberle, Jane E. Hobson, Oren Livne, Jennifer Ancona Semko, Randall B. Sunberg, Xin Tao, Olivia Tyrrell, Alan F. Zoccolillo, Jr. and Lois Sheng Liu

Germany’s implementation of the European Accessibility Act (EAA) – Are medical devices affected?

Medical Devices May 2, 2025

US Tariffs and the Life Science industry – an update

Following our previous post here, we provide an update on the current developments in this area. On April 2, 2025, the US administration announced…

Digital Health April 11, 2025

The Healthcare Agenda of Germany’s New CDU/SPD Coalition Government – A Point-by-Point Analysis of Key Policies and Their Potential Implications for Pharma and Med-Tech Companies

In brief The newly negotiated Coalition Agreement between Germany’s center-right CDU and center-left SPD political parties outlines a healthcare policy agenda with implications for…

Medical Devices March 26, 2025

Switzerland’s Therapeutic Products Act Revision: Industry Stakeholders Show Positive Support

I. Overview of proposed key changes The Swiss Federal Act on Medicinal Products and Medical Devices (Swiss Therapeutic Products Act, TPA), which has…

EU Pharmaceutical Package

In EU Pharmaceutical Package

A New Dawn for the EU Pharma Regulatory Regime? The Commission’s Proposal to Revise the EU Pharmaceutical Legislation is Finally Published

April 26, 2023 by Els Janssens, Magda Tovar and Julia Gillert 5 Mins Read

Today the European Commission has finally published its Proposal to revise the EU Pharmaceutical legislation, the most momentous…

In EU Pharmaceutical Package

EU Pharma Package: How Significant are the Proposals for Orphan Medicines?

May 16, 2023 by Els Janssens, Magda Tovar and Julia Gillert 6 Mins Read

On 26 April 2023 the European Commission published its Proposals to Reform the EU pharmaceutical legislation.[1] We continue…

In EU Pharmaceutical Package

Hungarian Pricing and Reimbursement Reforms Aiming to Remove Hurdles to Late Market Access of Innovative Pharmaceuticals

May 26, 2023 by Dr. Helga Bíró M.Jur. and Máté Laczkó 3 Mins Read

In brief Reimbursing medicinal products is critical to ensure that treatments are widely available to patients. This is…

In EU Pharmaceutical Package

The EU Pharmaceutical Package From a National Perspective: Member States’ First Reactions

May 30, 2023 by Els Janssens, Julie Yeni, Dr. Martin Altschwager LL.M., Dr. Frank Pflueger and Magda Tovar 6 Mins Read

The Proposal to revise the EU Pharmaceutical legislation has generated unprecedented levels of attention, not only across the…

In EU Pharmaceutical Package

The Future is Green: Eco Measures are Embedded into the EU Reform Proposals

June 13, 2023 by Julia Gillert, Els Janssens and Magda Tovar 2 Mins Read

As previously covered in this blog, on 26 April 2023 the European Commission published a set of proposals…

In EU Pharmaceutical Package

Supply Chain Protection: What do the EU Reform Proposals Look Like and do They go Far Enough?

June 13, 2023 by Julia Gillert, Els Janssens and Magda Tovar 3 Mins Read

As already well noted on this blog, on 26 April 2023 the European Commission published a set of…